<DOC>
	<DOCNO>NCT00511862</DOCNO>
	<brief_summary>This study evaluate Liver Progression Free Survival ( PFS ) safety TheraSphere treatment dose 120 Gy +/1 10 % patient least 18 year age diagnose metastatic disease liver treat progress follow treatment systemic liver-directed therapy .</brief_summary>
	<brief_title>TheraSphere Treatment Liver Metastases</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Carcinoma , Neuroendocrine</mesh_term>
	<criteria>18 year age old diagnosis metastatic disease liver refractory , inappropriate , systemic liverdirected therapy unresectable liver metastasis target tumor measurable use standard image technique tumor replacement &lt; = 50 % total liver volume ( visual estimation investigator ) Hypervascular tumor ( visual estimation investigator ) Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 minimum one month since recent prior cancer therapy exception patient receive Sandostatin neuroendocrine cancer patient inform consent At risk hepatic renal failure within 21 day treatment ( serum creatinine &gt; 2.0 mg/dL unless dialysis ; serum bilirubin â‰¥ 2.0 mg/dL ; albumin &lt; 2.0 mg/dL history hepatic encephalopathy ) contraindication angiography selective visceral catheterization include noncorrectable bleeding diathesis coagulopathy , severe peripheral vascular disease history nonmanagement allergy intolerance contrast , narcotic , sedative atropine severe liver dysfunction presentation pulmonary insufficiency clinically evident history chronic obstructive pulmonary disease cirrhosis portal hypertension prior external beam radiation treatment liver prior TheraSphere treatment liver intervention , compromise Ampulla Vater clinically evident ascites ( trace ascites image acceptable ) continue complication prior cancer therapy improve resolve prior 21 day first TheraSphere treatment significant lifethreatening extrahepatic disease judgment physician concurrent enrollment another study alternative available therapy judgement physician evidence technetium99m macroaggregated albumin scan show lung shunt &gt; 30 Gy cumulative limit evidence technetium99m macroaggregated albumin scan show potential deposition microspheres gastrointestinal tract eliminate catheter placement corrective action use standard angiographic technique positive serum pregnancy test woman childbearing potential comorbid disease condition put patient undue risk precludes use TheraSphere judgment physician</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>TheraSphere</keyword>
	<keyword>radioactive microspheres</keyword>
	<keyword>Yttrium-90</keyword>
	<keyword>Yttrium glass microspheres</keyword>
</DOC>